Abstract 3158: Pharmacokinetic and biodistribution evaluation of nebivolol and dasatinib in the 4T1 triple-negative breast cancer model: Implications for drug-drug interactionAirong Li, Diana S.-L. Chow, Amir Mohammad Gholizadeh et al.|Cancer Research|2026Cited by 1
Abstract 4464: Repurposing nebivolol with CPI-613 for triple-negative breast cancer: Linking <i>in-vitro</i> synergy to <i>in-vivo</i> exposure.Mikayla Skillman, Diana S.-L. Chow, Airong Li et al.|Cancer Research|2026Cited by 0